Download - Cadth 2015 c1 april 13th klee
Impact of HTA Therapeutic Reviews on
Real World Clinical Practice: The MS
Society of Canada’s Perspective
Dr. Karen Lee, Vice-President Research
• Reduce relapse disability• Reduce relapse rate
• Reduce or stop progression• Remyelination• Neuroprotection
10 therapies approved in Canada with more in the pipeline
0 therapies available
“ I believe I would be in a wheelchair without this medicine so I continue giving myself an injection once a day until a cure is found”
“ I would be interested in trying new drugs if they have minimal side effects and were taken orally rather than injection base.”
Views on the Therapeutic Review
• Assumes all people living with MS are alike, does not take into account the variability in the MS population
• Restrictive nature of recommendations, does not allow for choice and personalized medicine approach
• Focused on cost effectiveness versus the person living with MS